



## Ongoing Trials – status update

### GOG 3015 (NCT03038100)



### CP + Bevacizumab +/- Atezolizumab



(Global)

#### YO39523/GOG-3015/ENGOT-ov39

- Previously untreated high-grade cancer
- Stage III macroscopic or Stage IV (allows election of NACT), Bx cohort
- Stratification PDL1 0 vs 1+, Stage, PS, NACT
- Co-Primary endpoints (PDL1+): OS HR 0.72 (81%, 0.046), PFS HR 0.7



Open: MAR 2017

Status: Ongoing Accrual

Target: 1300 pts

Notes: Joint protocol steering committee (GNE, GOG-F, ENGOT)



Moore K and Pignata S, for GOG-F and ENGOT